1 ANNEX, Commission Regulation (EU) No 900/2014 of 15 July 2014 amending, for the purpose of its…

In forcesince 15 Jul 2014

The Annex to Regulation (EC) No 440/2008 is amended as follows:

Chapters B.53, B.54, B.55, B.56, B.57 and B.58 are inserted:

1.

This test method is equivalent to OECD Test Guideline (TG) 426 (2007). In Copenhagen in June 1995, an OECD Working Group on Reproduction and Developmental Toxicity discussed the need to update existing OECD test guidelines for reproduction and developmental toxicity, and the development of new guidelines for endpoints not yet covered (1). The working group recommended that a test guideline for developmental neurotoxicity should be written based on a US EPA guideline, which has since been revised (2). In June 1996, a second consultation meeting was held in Copenhagen to provide the Secretariat with guidance on the outline of a new test guideline on developmental neurotoxicity, including the major elements, e.g. details concerning choice of animal species, dosing period, testing period, endpoints to be assessed, and criteria for evaluating results. A US neurotoxicity risk assessment guideline was published in 1998 (3). An OECD Expert Consultation Meeting and an ILSI Risk Science Institute Workshop were held back-to-back in October 2000 and an expert consultation meeting was held in Tokyo 2005. These meetings were held to discuss the scientific and technical issues related to the current test guideline and the recommendations from the meetings (4)(5)(6)(7) were considered in the development of this test method. Additional information on the conduct, interpretation and terminology used for this test method can be found in OECD Guidance Documents No 43 on “Reproductive Toxicity Testing and Assessment” (8) and No 20 on “Neurotoxicity Testing” (9).

2.

A number of chemicals is known to produce developmental neurotoxic effects in humans and other species (10)(11)(12)(13). Determination of the potential for developmental neurotoxicity may be needed to assess and evaluate the toxic characteristics of a chemical. Developmental neurotoxicity studies are designed to provide data, including dose-response characterisations, on the potential functional and morphological effects on the developing nervous system of the offspring that may arise from exposure in utero and during early life.

3.

A developmental neurotoxicity study can be conducted as a separate study, incorporated into a reproductive toxicity and/or adult neurotoxicity study (e.g. test methods B.34 (14), B.35 (15), B.43 (16)), or added onto a prenatal developmental toxicity study (e.g. test method B.31 (17)). When the developmental neurotoxicity study is incorporated within or attached to another study, it is imperative to preserve the integrity of both study types. All testing should comply with applicable legislation or government and institutional guidelines for the use of laboratory animals in research (e.g. 18).

4.

The testing laboratory should consider all available information on the test chemical prior to conducting the study. Such information will include the identity and structure of the chemical; its physico-chemical properties; the results of any other in vitro or in vivo toxicity tests on the chemical; toxicological data on structurally related chemicals; and the anticipated use(s) of the chemical. This information is necessary to satisfy all concerned that the test is relevant for the protection of human health, and will help in the selection of an appropriate starting dose.

5.

The test chemical is administered to animals during gestation and lactation. Dams are tested to assess effects in pregnant and lactating females and may also provide comparative information (dams versus offspring). Offspring are randomly selected from within litters for neurotoxicity evaluation. The evaluation consists of observations to detect gross neurologic and behavioural abnormalities, including the assessment of physical development, behavioural ontogeny, motor activity, motor and sensory function, and learning and memory; and the evaluation of brain weights and neuropathology during postnatal development and adulthood.

6.

When the test method is conducted as a separate study, additional available animals in each group could be used for specific neurobehavioral, neuropathological, neurochemical or electrophysiological procedures that may supplement the data obtained from the examinations recommended by this test method (16)(19)(20)(21). The supplemental procedures can be particularly useful when empirical observation, anticipated effects, or mechanism/mode-of-action indicate a specific type of neurotoxicity. These supplemental procedures may be used in the dams as well as in the pups. In addition, ex vivo or in vitro procedures may also be used, as long as these procedures do not alter the integrity of the in vivo procedures.

7.

The preferred test species is the rat; other species can be used when appropriate. Note, however, the gestational and postnatal days specified in this test method are specific to commonly used strains of rats, and comparable days should be selected if a different species or unusual strain is used. The use of another species should be justified based on toxicological, pharmacokinetic, and/or other data. Justification should include availability of species-specific postnatal neurobehavioral and neuropathological assessments. If there was an earlier test that raised concerns, the species/strain that raised a concern should be considered. Because of the differing performance attributes of different rat strains, there should be evidence that the strain selected for use has adequate fecundity and responsiveness. The reliability and sensitivity of other species to detect developmental neurotoxicity should be documented.

8.

The temperature in the experimental animal room should be 22 ± 3 °C. Although the relative humidity should be at least 30 % and preferably not exceed 70 % other than during room cleaning, the aim should be 50-60 %. Lighting should be artificial, the sequence being 12 hours light, 12 hours dark. It is also possible to reverse the light cycle prior to mating and for the duration of the study, in order to perform the assessments of functional and behavioural endpoints during the dark period (under red light), i.e. during the time the animals are normally active (22). Any changes in the light-dark cycle should include adequate acclimation time to allow animals to adapt to the new cycle. For feeding, conventional laboratory diets may be used with an unlimited supply of drinking water. The type of food and water should be reported and both should be analysed for contaminants.

9.

Animals may be housed individually or be caged in small groups of the same sex. Mating procedures should be carried out in cages suitable for the purpose. After evidence of copulation or no later than day 15 of pregnancy, mated animals should be caged separately in delivery or maternity cages. Cages should be arranged in such a way that possible effects due to cage placement are minimised. Mated females should be provided with appropriate and defined nesting materials when parturition is near. It is well known that inappropriate handling or stress during pregnancy can result in adverse outcomes, including prenatal loss and altered foetal and postnatal development. To guard against foetal loss from factors which are not treatment-related, animals should be carefully handled during pregnancy, and stress from outside factors such as excessive outside noise should be avoided.

10.

Healthy animals should be used, which have been acclimated to laboratory conditions and have not been subjected to previous experimental procedures, unless the study is incorporated in another study (see paragraph 3). The test animals should be characterised as to species, strain, source, sex, weight and age. Each animal should be assigned and marked with a unique identification number. The animals of all test groups should, as nearly as practicable, be of uniform weight and age, and should be within the normal range of the species and strain under study. Young adult nulliparous female animals should be used at each dose level. Siblings should not be mated, and care should be taken to ensure this. Gestation Day (GD) 0 is the day on which a vaginal plug and/or sperm are observed. Adequate acclimation time (e.g. 2-3 days) should be allowed when purchasing time-pregnant animals from a supplier. Mated females should be assigned in an unbiased way to the control and treatment groups, and as far as possible, they should be evenly distributed among the groups (e.g. a stratified random procedure is recommended to provide even distribution among all groups, such as that based on body weight). Females inseminated by the same male should be equalised across groups.

11.

Each test and control group should contain a sufficient number of pregnant females to be exposed to the test chemical to ensure that an adequate number of offspring are produced for neurotoxicity evaluation. A total of 20 litters are recommended at each dose level. Replicate and staggered-group dosing designs are allowed if total numbers of litters per group are achieved, and appropriate statistical models are used to account for replicates.

12.

On or before postnatal day (PND) 4 (day of delivery is PND 0), the size of each litter should be adjusted by eliminating extra pups by random selection to yield a uniform litter size for all litters (23). The litter size should not exceed the average litter size for the strain of rodents used (8-12). The litter should have, as nearly as possible, equal numbers of male and female pups. Selective elimination of pups, e.g. based upon body weight, is not appropriate. After standardisation of litters (culling) and prior to further testing of functional endpoints, individual pups that are scheduled for pre-weaning or post-weaning testing should be identified uniquely, using any suitable humane method for pup identification (e.g. 24).

13.

The test method allows various approaches with respect to the assignment of animals exposed in utero and through lactation to functional and behavioural tests, sexual maturation, brain weight determination, and neuropathological evaluation (25). Other tests of neurobehavioral function (e.g. social behaviour), neurochemistry or neuropathology can be added on a case-by-case basis, as long as the integrity of the original required tests are not compromised.

14.

Pups are selected from each dose group and assigned for endpoint assessments on or after PND 4. Selection of pups should be performed so that to the extent possible both sexes from each litter in each dose group are equally represented in all tests. For motor activity testing the same pair of male and female pups should be tested at all pre-weaning ages (see paragraph 35). For all other tests the same or separate pairs of male and female animals may be assigned to different behavioural tests. Different pups may need to be assigned to weanling versus adult tests of cognitive function in order to avoid confounding the effects of age and prior training on these measurements (26)(27). At weaning (PND 21), pups not selected for testing can be disposed of humanely. Any alterations in pup assignments should be reported. The statistical unit of measure should be the litter (or dam) and not the pup.

15.

There are different ways to assign pups to the pre-weaning and post-weaning examinations, cognitive tests, pathological examinations, etc., (see Figure 1 for general design and Appendix 1 for examples of assignment). Recommended minimum numbers of animals in each dose group for pre-weaning and post-weaning examinations are as follows:

[Depending on the sensitivity of cognitive function tests, investigation of a large higher number of animals should be considered e.g. up to 1 male and 1 female per litter (for animal assignments see Appendix 1) (further guidance on sample size is provided in the OECD Guidance Document 43 (8)).]

Clinical observations and bodyweight | All animals

Detailed clinical observations | 20/sex (1/sex/litter)

Brain weight (post fixation) PND 11-22 | 10/sex (1/litter)

Brain weight (unfixed) ~ PND 70 | 10/sex (1/litter)

Neuropathology (immersion or perfusion fixation) PND 11-22 | 10/sex (1/litter)

Neuropathology (perfusion fixation) PND ~ 70 | 10/sex (1/litter)

Sexual maturation | 20/sex (1/sex/litter)

Other developmental landmarks (optional) | All animals

Behavioural ontogeny | 20/sex (1/sex/litter)

Motor activity | 20/sex (1/sex/litter)

Motor and sensory function | 20/sex (1/sex/litter)

Learning and memory | 10/sex (1/litter)

16.

At least three dose levels and a concurrent control should be used. The dose levels should be spaced to produce a gradation of toxic effects. Unless limited by the physico-chemical nature or biological properties of the chemical, the highest dose level should be chosen with the aim to induce some maternal toxicity (e.g. clinical signs, decreased body weight gain (not more than 10 %) and/or evidence of dose-limiting toxicity in a target organ). The high dose may be limited to 1000 mg/kg/day body weight, with some exceptions. For example, expected human exposure may indicate the need for a higher dose level to be used. Alternatively, pilot studies or preliminary range-finding studies should be performed to determine the highest dosage to be used which should produce a minimal degree of maternal toxicity. If the test chemical has been shown to be developmentally toxic either in a standard developmental toxicity study or in a pilot study, the highest dose level should be the maximum dose which will not induce excessive offspring toxicity, or in utero or neonatal death or malformations, sufficient to preclude a meaningful evaluation of neurotoxicity. The lowest dose level should aim to not produce any evidence of either maternal or developmental toxicity including neurotoxicity. A descending sequence of dose levels should be selected with a view to demonstrating any dose-related response and a No-Observed-Adverse Effect Level (NOAEL), or doses near the limit of detection that would allow the determination of a benchmark dose. Two- to four-fold intervals are frequently optimal for setting the descending dose levels, and the addition of a fourth dose group is often preferable to using very large intervals (e.g. more than a factor of 10) between dosages.

17.

Dose levels should be selected taking into account all existing toxicity data as well as additional information on metabolism and toxicokinetics of the test chemical or related materials. This information may also assist in demonstrating the adequacy of the dosing regimen. Direct dosing of pups should be considered based on exposure and pharmacokinetic information (28)(29). Careful consideration of benefits and disadvantages should be made prior to conducting direct dosing studies (30).

18.

The concurrent control group should be a sham-treated control group or a vehicle-control group if a vehicle is used in administering the test chemical. All animals should normally be administered the same volume of either test chemical or vehicle on a body weight basis. If a vehicle or other additive is used to facilitate dosing, consideration should be given to the following characteristics: effects on the absorption, distribution, metabolism, or retention of the test chemical; effects on the chemical properties of the test chemical which may alter its toxic characteristics; and effects on the food or water consumption or the nutritional status of the animals. The vehicle should not cause effects that could interfere with the interpretation of the study neither should it be neurobehaviourally toxic nor have effects on reproduction or development. For novel vehicles, a sham-treated control group should be included in addition to a vehicle control group. Animals in the control group(s) should be handled in an identical manner to test group animals.

19.

The test chemical or vehicle should be administered by the route most relevant to potential human exposure, and based on available metabolism and distribution information in the test animals. The route of administration will generally be oral (e.g.gavage, dietary, via drinking water), but other routes (e.g. dermal, inhalation) may be used depending on the characteristics and anticipated or known human exposure routes (further guidance is provided in the Guidance Document 43(8)). Justification should be provided for the route of administration chosen. The test chemical should be administered at approximately the same time every day.

20.

The dose administered to each animal should normally be based on the most recent individual body weight determination. However, caution should be exercised when adjusting the doses during the last third of pregnancy. If excess toxicity is noted in the treated dams, those animals should be humanely killed.

21.

The test chemical or vehicle should, as a minimum, be administered daily to mated females from the time of implantation (GD 6) throughout lactation (PND 21), so that the pups are exposed to the test chemical during pre- and postnatal neurological development. The age at which dosing starts, and the duration and frequency of dosing, may be adjusted if evidence supports an experimental design more relevant to human exposures. Dosing durations should be adjusted for other species to ensure exposure during all early periods of brain development (i.e. equivalent to prenatal and early postnatal human brain growth). Dosing may begin from the initiation of pregnancy (GD 0) although consideration should be given to the potential of the test chemical to cause pre-implantation loss. Administration beginning at GD 6 would avoid this risk, but the developmental stages between GD 0 and 6 would not be treated. When a laboratory purchases time-mated animals, it is impractical to begin dosing at GD 0, and thus GD 6 would be a good starting day. The testing laboratory should set the dosing regimen according to relevant information about the effects of the test chemical, prior experience, and logistical considerations; this may include extension of dosing past weaning. Dosing should not occur on the day of parturition in those animals which have not completely delivered their offspring. In general, it is assumed that exposure of the pups will occur through the maternal milk; however, direct dosing of pups should be considered in those cases where there is a lack of evidence of continued exposure to offspring. Evidence of continuous exposure can be retrieved from e.g. pharmacokinetic information, offspring toxicity or changes in bio-markers (28).

22.

All dams should be carefully observed at least once daily with respect to their health condition, including morbidity and mortality.

23.

During the treatment and observation periods, more detailed clinical observations should be conducted periodically (at least twice during the gestational dosing period and twice during the lactational dosing period) using at least 10 dams per dose level. The animals should be observed outside the home cage by trained technicians who are unaware of the animals' treatment, using standardised procedures to minimise animal stress and observer bias, and maximise inter-observer reliability. Where possible, it is advisable that the observations in a given study be made by the same technician.

24.

The presence of observed signs should be recorded. Whenever feasible, the magnitude of the observed signs should also be recorded. Clinical observations should include, but not be limited to, changes in skin, fur, eyes, mucous membranes, occurrence of secretions, and autonomic activity (e.g. lacrimation, piloerection, pupil size, unusual respiratory pattern and/or mouth breathing, and any unusual signs of urination or defecation).

25.

Any unusual responses with respect to body position, activity level (e.g. decreased or increased exploration of the standard area) and co-ordination of movement should also be noted. Changes in gait, (e.g. waddling, ataxia), posture (e.g. hunched-back) and reactivity to handling, placing or other environmental stimuli, as well as the presence of clonic or tonic movements, convulsions, tremors, stereotypies (e.g.excessive grooming, unusual head movements, repetitive circling), bizarre behaviour (e.g. biting or excessive licking, self-mutilation, walking backwards, vocalisation), or aggression should be recorded.

26.

Signs of toxicity should be recorded, including the day of onset, time of day, degree, and duration.

27.

Animals should be weighed at the time of dosing at least weekly throughout the study, on or near the day of delivery, and on PND 21 (weaning). For gavage studies dams should be weighed at least twice weekly. Doses should be adjusted at the time of each body weight determination, as appropriate. Food consumption should be measured weekly at a minimum during gestation and lactation. Water consumption should be measured at least weekly if exposure is via the water supply.

28.

All offspring should be carefully observed at least daily for signs of toxicity and for morbidity and mortality.

29.

During the treatment and observation periods, more detailed clinical observations of the offspring should be conducted. The offspring (at least one pup/sex/litter) should be observed by trained technicians who are unaware of the animals' treatment, using standardised procedures to minimise bias and maximise inter-observer reliability. Where possible, it is advisable that the observations are made by the same technician. At a minimum, the endpoints described in paragraphs 24 and 25 should be monitored as appropriate for the developmental stage being observed.

30.

All signs of toxicity in the offspring should be recorded, including the day of onset, time of day, degree, and duration.

31.

Changes in pre-weaning landmarks of development (e.g.pinna unfolding, eye opening, incisor eruption) are highly correlated with body weight (30)(31). Body weight may be the best indicator of physical development. Measurement of developmental landmarks is, therefore, recommended only when there is prior evidence that these endpoints will provide additional information. Timing for the assessment of these parameters is indicated in Table 1. Depending on the anticipated effects, and the results of the initial measurements, it may be advisable to add additional time points or to perform the measurements in other developmental stages.

32.

It is advisable to use post-coital age instead of postnatal age when assessing physical development (33). If pups are tested on the day of weaning, it is recommended that this testing be carried out prior to actual weaning to avoid a confounding effect by the stress associated with weaning. In addition, any post-weaning testing of pups should not occur during the two days after weaning.

This article is long: the rest is at the official publication.